
Conditions affecting the selection of individuals for a study are a common source of bias in epidemiological and medical research. A recent trend in epidemiology has been to link selection conditions to the concept of collider variables. The effects of selection and associated collider variables depend on the composition of the study population, the study selection process, the target of inference, and methods of data collection and analysis. We give here an introduction to bias arising from selection effects, termed selection collider bias, and discuss ways of avoiding it. We provide illustrations related to two apparent paradoxes in rheumatology that involve smoking. The first paradox is that smoking, a risk factor for rheumatoid arthritis (RA), appears to be protective for disease progression in RA. The second is that smoking is a risk factor for psoriatic arthritis (PsA), but in some studies involving persons with psoriasis it appears to reduce the risk of PsA. Using data from the Gladman-Krembil Psoriatic Arthritis Research Program we examine the effect of smoking on the development of PsA in individuals with psoriasis and resolve the paradox. collider variables, confounding, directed acyclic graphs, observational data, selection effects.
Objective To compare a newly proposed Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cut-off for high disease activity (BASDAI≥2.5) with the corresponding Axial Spondyloarthritis Disease Activity Score (ASDAS) cut-off (ASDAS≥2.1) as an eligibility criterion for initiating a biologic disease-modifying antirheumatic drug (bDMARD) in routine care patients with axial spondyloarthritis (axSpA). Methods Real-world patients with axSpA initiating their first bDMARD from 9 European registries were analysed. Patients were categorised into 4 subgroups according to the fulfilment of ASDAS and BASDAI criteria at baseline, and treatment effect was assessed at 6 months using several response and remission outcomes. Adjusted logistic regression analyses were performed to determine whether fulfilling ASDAS and BASDAI criteria was associated with achieving the treatment outcomes. Results Of 6,329 patients included, 90.9% fulfilled both ASDAS and BASDAI eligibility criteria at baseline, 2.5% and 2.7% fulfilled either ASDAS or BASDAI criterion alone, while 3.8% fulfilled neither. The subgroup fulfilling both criteria demonstrated the highest responses at 6 months, while the highest remission outcomes were observed in the subgroup fulfilling neither criterion. Fulfilling either criterion at baseline was significantly associated with achieving response outcomes at 6 months, whereas a negative association was observed for remission outcomes. Conclusion In a multinational European cohort, a very large overlap between the BASDAI and the ASDAS eligibility criteria was shown, and the predictive ability of the two criteria to achieve treatment outcomes was comparable. These findings support the use of BASDAI≥2.5 as a criterion for initiating bDMARD therapy in axSpA, particularly when ASDAS is unavailable.
Calcinosis affects 20% to 40% of patients with juvenile dermatomyositis (JDM), and is associated in particular with antinuclear matrix protein 2 (anti-NXP2) antibodies, younger age at disease onset, and persistent disease activity.1-3 Extensive calcinosis beginning in early childhood is rare. No treatment is uniformly effective, although Janus kinase ( JAK) inhibitors have emerged as an option for refractory calcinosis.2,4
Erythropoiesis (EPO)-stimulating agents (ESAs) are recommended first-line therapy for symptomatic anemia in lower-risk myelodysplastic syndrome (MDS), reducing transfusion dependence in 40% to 60% of eligible patients.1 Arthralgia and myalgia are recognized side effects of ESAs,1 but evident inflammatory monoarthritis directly attributable to ESA therapy has not, to our knowledge, been previously reported.